Effect of allopurinol on prevention of pancreatitis after Endoscopic Retrograde Cholangio Pancreatography(ERCP)

A double blind randomized clinical trial to evaluate the effect of oral allopurinol on the prevention of post ERCP pancreatitis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000182998

Enrollment

500

Registered

2011-02-15

Start date

2010-02-10

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

ERCP pancreatitis is a frequent complication either for diagnosis or treatment of pancreatobiliary diseases. A number of pharmacological agents have been tried for prevention or alleviation of the complication. Allopurinol with free radical scavenger property has been considered as an effective prophylactic agent in some clinical trials. Administration of Allopurinol in these trials was done in a long period before doing ERCP. Hence Allopurinol converts to oxupurinol in the liver rapidly; it seems that clinical judgment about the net effect of Allopurinol on prevention of post ERCP pancreatitis is doubtful.Aim of present study is to determine effect of allopurinol in prevention of post ERCP pancreatitis by changing time administration of allopurinol compared with previous studies.

Interventions

administration of oral allopurinol 300 mg twice daily for 1 day

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Prevention

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Healthy volunteers

Inclusion criteria

all patients above 20 years old undergoing ERCP in the gastrointestinal and liver diseases ward of Talighani hospital (Tehran, Iran) with informed consent

Exclusion criteria

patients with renal failure or patients with bone marrow suppression ,those who had developed acute pancreatitis during 2 weeks before ERCP, pregnant women, patient who took azathioprine and those who didn’t agree to participate in the study.

Outcome results